UH Seidman Cancer Center

UH Seidman Cancer Center Leadership

Ted Teknos, MD 

Theodoros N. Teknos, MD

President and Scientific Officer of University Hospitals Seidman Cancer Center

Dr. Teknos leads the development of strategic, business and marketing plans for UH Seidman, including cancer-related palliative care, integrative care and interface with UH Hospice care. He oversees all inpatient and ambulatory cancer care delivered at facilities across the UH system. Dr. Teknos provides leadership of UH Seidman’s academic components and the Clinical Trials Unit. He directs UH Seidman’s involvement in the Case Comprehensive Cancer Center.

Dr. Teknos earned his medical degree from Harvard Medical School. He completed his otolaryngology residency at Massachusetts Eye and Ear Infirmary/Harvard Combined Program, Boston, and a fellowship in head and neck oncology, skull base and microvascular reconstruction at Vanderbilt University Medical Center in Nashville.

Contact Dr. Teknos at 216-844-6000

Jeffrey Hardacre, MD 

Jeffrey Hardacre, MD

Chair, Surgical Oncology Quality Committee, UH Cleveland Medical Center, Interim Chief Medical Officer, UH Seidman Cancer Center and Professor of Surgery, Case Western Reserve University School of Medicine

Responsible for quality and inpatient clinical services for the cancer hospital.

Contact Dr. Hardacre at 216-844-7047

Mitchell Machtay, MD 

Mitchell Machtay, MD

Chairman, Department of Radiation Oncology, UH Cleveland Medical Center and Case Western Reserve University School of Medicine; Vincent K. Smith Chair in Radiation Oncology, UH Cleveland Medical Center; and Professor, Case Western Reserve University School of Medicine

Regarded as a national clinical research leader in radiation oncology. Dr. Machtay’s areas of interest and expertise include lung cancer, head and neck cancer and tumors within or near the central nervous system

In his position, he works closely with the clinical investigators at UH Seidman Cancer Center. He is nationally recognized for his outstanding leadership, serving as the deputy chair of the Radiation Therapy Oncology Group (RTOG) since 2000. The RTOG is the major coordinating center for clinical trials in radiation therapy in the country. Dr. Machtay is on the editorial board for the International Journal of Radiation Oncology- Biology-Physics. He also has been an editorial board member of several medical journals and has delivered numerous national and international presentations. 

Contact Dr. Machtay at 216-844-2530


Sanford Markowitz, MD 

Sanford Markowitz, MD, PhD

Medical Oncologist, UH Seidman Cancer Center; Francis Wragg Ingalls Professor of Cancer Genetics, Case Western Reserve University School of Medicine

A team of researchers published findings in the April issue of Science Translational Medicine on the effects of aspirin on colorectal cancer risk in people with the gene 15-hydroxyprostaglandin dehydrogenase (15-PGDH) RNA. The study, which included nearly 128,000 participants, found that people with high levels of 15-PGDH in their colons could cut their colorectal cancer risk in half by taking aspirin. Researchers now hope to develop a cost-effective test for measuring the levels of 15-PGDH in the colon to determine which patients would benefit from aspirin therapy. 

Contact Dr. Markowitz at 216-844-3951

Afshin Dowlati, MD 

Afshin Dowlati, MD

Director, Thoracic Oncology Program, Rosalie and Morton A. Cohen Chair in Oncology, Endowed Director of the Gries Center for Cancer Drug Development, UH Seidman Cancer Center; and Professor of Medicine, Case Western Reserve University School of Medicine

The Research team published two studies that have the potential to advance the treatment of small cell lung cancer (SCLC), one of the fastest-growing cancers

The first study, published in the Journal of Thoracic Oncology, found a new mutation in SCLC, called RET, that was linked to rapid cell growth. Examining specimens in its database of metastatic SCLC tumors, the team discovered that the RET protein was sensitive to two new targeted therapies, ponatinib and vandetanib. The second study, published in PLOS One, focused on analyzing SCLC tumors to examine drug sensitivity to predict which drugs would be most effective at slowing tumor growth.

Contact Dr. Dowlati at 216-844-1228


Back to Top